Antiepileptic drugs

Side Effects of Drugs Annual

Volumn 31, Issue C, 2009, Pages 105-148

  Schmidt, Dieter ^a   Beyenburg, Stefan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954640052     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(09)03107-9     Document Type: Article

References (179)

1. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kälväinan R, Mattson R, Perucca E, Tomson T. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7): 1094-120.
2. Aronson JK. Industry-sponsored clinical research-an editor's view. In: Halkin H, Tal O, editors. Patients, physicians, and pharma. Haifa: The Israel National Institute for Health Policy Research; 2006, p. 15-28.
3. Apeland T, Kristensen O, Strandjord RE, Mansoor MA. Thyroid function during B-vitamin supplementation of patients on antiepileptic drugs. Clin Biochem 2006;39:282-6.
4. Sener U, Zorlu Y, Karaguzel O, Ozdamar O, Coker I, Topbas M. Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6. Seizure 2006;15: 79-85.
5. Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006;66(9):1318-24.
6. Tekgul H, Serdaroglu G, Huseyinov A, Gokben S. Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy. J Child Neurol 2006;21(5):411-4.
7. Nicolaidou P, Georgouli H, Kotsalis H, Matsinos Y, Papadopoulou A, Fretzayas A, Syriopoulou V, Krikos X, Karantana A, Karpathios T. Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J Child Neurol 2006;21(3):205-9.
8. Pack AM. Therapy insight: clinical management of pregnant women with epilepsy. Nat Clin Pract Neurol 2006;2(4):190-200.
9. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC. NEAD Study Group. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006;67:407-12.
10. Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf 2006;29(2):95-118.
11. Gamble C, Williamson PR, Chadwick DW, Marson AG. A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology 2006;66:1310-7.
12. Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006;129: 1281-92.
13. Äikiä M, Jutila L, Salmenpera T, Mervaala E, Kälviäinen R. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. Epilepsia 2006;47:1121-7.
14. Castro-Gago M, Novo-Rodríguez MI, Blanco-Barca MO, Urisarri-Ruíz de CortÃzar A, Rodríguez-García J, Rodríguez-Segade S, Eirís-Punal J. Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital. J Child Neurol 2006;21:48-53.
15. Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, Egberts TC, van den Bemt PM. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006;47:1232-6.
16. Peyriere H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, Hillaire-Buys DNetwork of the French Pharmacovigilance Centers. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006;155:422-8.
17. Yun SJ, Lee JB, Kim EJ, Quan G, Kim SJ, Won YH, Lee SC. Drug rash with eosinophilia and systemic symptoms induced by valproate and carbamazepine: formation of circulating auto-antibody against 190-kDa antigen. Acta Derm Venereol 2006;86: 241-4.
18. Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006;35:177-81.
19. So JS, Edwards SL, Ibbotson SH. Carbamazepine-induced hypersensitivity syndrome occurring in a photodistributed pattern. Dermatology 2006;213:166-8.
20. Hessen E, Lossius MI, Reinvang I, Gjerstad L. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia 2006;47:2038-45.
21. Pilo C, Wide K, Winbladh B. Pregnancy, delivery, and neonatal complications after treatment with antiepileptic drugs. Acta Obstet Gynecol Scand 2006;85:643-6.
22. Viinikainen K, Heinonen S, Eriksson K, Kälväinan R. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006;47:186-92.
23. Oskay T, Karademir A, Ertürk OI. Association of anticonvulsant hypersensitivity syndrome with herpesvirus 6, 7. Epilepsy Res 2006;70:27-40.
24. Obermoser G, Zelger B. Fever, eosinophilia, and a rash. J Am Acad Dermatol 2006;54:913-4.
25. Brahmi N, Kouraichi N, Thabet H, Amamou M. Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. Am J Emerg Med 2006;24:440-3.
26. Bates DE, Herman RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann Pharmacother 2006;40: 1190-5.
27. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006;61:58-69.
28. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan Y. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 2006;62:291-6.
29. Carbone A, Palleschi G, Conte A, Bova G, Iacovelli E, Bettolo RM, Pastore A, Inghilleri M. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol 2006;29:206-14.
30. Adam F, Menigaux C, Sessler DI, Chauvin M. A single preoperative dose of gabapentin (800 milligrams) does not augment post-operative analgesia in patients given interscalene brachial plexus blocks for arthroscopic shoulder surgery. Anesth Analg 2006;103:1278-82.
31. Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, Nunes EV. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 2006;81:267-74.
32. Nikolajsen L, Finnerup NB, Kramp S, Vimtrup AS, Keller J, Jensen TS. A randomized study of the effects of gabapentin on postamputation pain. Anesthesiology 2006;105:1008-15.
33. Sihoe AD, Lee TW, Wan IY, Thung KH, Yim AP. The use of gabapentin for post-operative and post-traumatic pain in thoracic surgery patients. Eur J Cardiothorac Surg 2006;29:795-9.
34. Shery T, Proudlock FA, Sarvananthan N, McLean RJ, Gottlob I. The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. Br J Ophthalmol 2006;90:839-43.
35. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain-a systematic review of randomized controlled trials. Pain 2006;126:91-101.
36. Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology 2006;44:1317-23.
37. Leung JM, Sands LP, Rico M, Petersen KL, Rowbotham MC, Dahl JB, Ames C, Chou D, Weinstein P. Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology 2006;67:1251-3.
38. Mikkelsen S, Hilsted KL, Andersen PJ, Hjortsø NC, Enggaard TP, Jørgensen DG, Hansen M, Henriksen J, Dahl JB. The effect of gabapentin on post-operative pain following tonsillectomy in adults. Acta Anaesthesiol Scand 2006;50:809-15.
39. Segerdahl M. Multiple dose gabapentin attenuates cutaneous pain and central sensitisation but not muscle pain in healthy volunteers. Pain 2006;125:158-64.
40. Reddy SY, Warner H, Guttuso Jr T, Messing S, DiGrazio W, Thornburg L, Guzick DS. Gabapentin, estrogen, and placebo for treat ing hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-8.
41. Rodrigues JP, Edwards DJ, Walters SE, Byrnes ML, Thickbroom GW, Stell R, Mastaglia FL. Blinded placebo crossover study of gabapentin in primary orthostatic tremor. Mov Disord 2006;21:900-5.
42. Turan A, Kaya G, Karamanlioglu B, Pamukçu Z, Apfel CC. Effect of oral gabapentin on postoperative epidural analgesia. Br J Anaesth 2006;96:242-6.
43. Turan A, White PF, Karamanlioglu B, Memis D, Tasdogan M, Pamukçu Z, Yavuz E. Gabapentin: an alternative to the cyclooxygenase-2 inhibitors for perioperative pain management. Anesth Analg 2006;102:175-81.
44. Hurley RW, Cohen SP, Williams KA, Rowlingson AJ, Wu CL. The analgesic effects of perioperative gabapentin on post-operative pain: a meta-analysis. Reg Anesth Pain Med 2006;31:237-47.
45. Holtkamp M, Halle A, Meierkord H, Masuhr F. Gabapentininduced severe myoclonus in a patient with impaired renal function. J Neurol 2006;253:382-3.
46. Kanbay M, Kaya A, Bozalan R, Aydogan T, Uz B, Isik A, Akcay A. Gabapentin induced edema in a geriatric patient. Clin Neuropharmacol 2006;29:186.
47. Rasimas JJ, Burkhart KK. Cardiac conduc tion disturbances after an overdose of nefazodone and gabapentin. Am J Emerg Med 2006;24:886-8.
48. Schaffer A, Zuker P, Levitt A. Rando mized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006;96:95-9.
49. Marken PA, Pies RW. Emerging treatments for bipolar disorder: safety and adverse effect profiles. Ann Pharmacother 2006;40:276-85.
50. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006;45:298-304.
51. Seemuller F, Dehning S, Grunze H, Muller N. Tourette's symptoms provoked by lamo trigine in a bipolar patient. Am J Psychiatry 2006;163:159.
52. Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, Mills K, Hammer A, Isojarvi J. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006;67:400-6.
53. Pressler RM, Binnie CD, Coleshill SG, Chorley GA, Robinson RO. Effect of lamotrigine on cognition in children with epilepsy. Neurology 2006;66:1495-9.
54. Raskin S, Teitelbaum A, Zislin J, Durst R. Adjunctive lamotrigine as a possible mania inducer in bipolar patients. Am J Psychiatry 2006;163:159-60.
55. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006;163: 1199-201.
56. Sachs G, Bowden C, Calabrese JR, Ketter T, Thompson T, White R, Bentley B. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8:175-81.
57. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, Resor Jr SR. Predictors of lamotrigine-associated rash. Epilepsia 2006;47:318-22.
58. Wolf R, Davidovici B, Matz H, Mahlab K, Orion E, Sthoeger ZM. Drug rash with eosinophilia and systemic symptoms versus Stevens-Johnson syndrome-a case that indicates a stumbling block in the current classification. Int Arch Allergy Immunol 2006;141:308-10.
59. Amlie-Lefond CM, Felgenhauer JL, Leong AD. Localized purpura associated with lamotrigine. Pediatr Neurol 2006;35:227-8.
60. Dubnov-Raz G, Shapiro R, Merlob P. Maternal lamotrigine treatment and elevated neonatal gamma-glutamyl transpeptidase. Pediatr Neurol 2006;35:220-2.
61. Page-Sharp M, Kristensen JH, Hackett LP, Beran RG, Rampono J, Hale TW, Kohan R, Ilett KF. Transfer of lamotrigine into breast milk. Ann Pharmacother 2006;40: 1470-1.
62. Contin M, Albani F, Ambrosetto G, Avoni P, Bisulli F, Riva R, Tinuper P, Baruzzi A. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia 2006;47:1573-5.
63. Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2006;61:191-9.
64. Specchio LM, Gambardella A, Giallonardo AT, Michelucci R, Specchio N, Boero G, La Neve A. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res 2006;71(1):32-9.
65. Kuba R, Novotna I, Brazdil M, Kocvarova J, Tyrlikova ; I, Mastik J, Rektor I. Long-term levetiracetam treatment of epilepsy patients: clinical audit. Epilepsy Res 2006;72 (2-3):111-9.
66. Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006;15(3):214-8.
67. Lambrechts DA, Sadzot B, van Paesschen W, van Leusden JA, Carpay J, Bourgeois P, Urbain E, Boon PA. Efficacy and safety of levetiracetam in clinical practice: results of the SKATE trial from Belgium and The Netherlands. Seizure 2006;15(6):434-42.
68. Patel NC, Landan IR, Levin J, Szaflarski J, Wilner AN. The use of levetiracetam in refractory status epilepticus. Seizure 2006;15(3):137-41.
69. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, Stockis A. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006;47(7):1128-35.
70. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, Lu Z. N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66(11):1654-60.
71. Stefan H, Wang-Tilz Y, Pauli E, Dennhofer S, Genow A, Kerling F, Lorber B, Fraun-berger B, Halboni P, Koebnick C, Gefeller O, Tilz C. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA). Epilepsia 2006; 47(3):516-22.
72. Tsai JJ, Yen DJ, Hsih MS, Chen SS, Hiersemenzel R, Edrich P, Lai CW. Effi cacy and safety of levetiracetam (up to 2000mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 2006;47(1):72-81.
73. Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E, Soorya L, Hollander E. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006;21(6):363-7.
74. Striano P, Coppola A, Vacca G, Zara F, Brescia Morra V, Orefice G, Striano S. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. J Neurol 2006;253(6):762-6.
75. Tarsy D, Ryan RK, Ro SI. An open-label trial of levetiracetam for treatment of cervical dystonia. Mov Disord 2006;21(5): 734-5.
76. Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 2006;29(3):148-53.
77. Meco G, Fabrizio E, Epifanio A, Morgante F, Valente M, Vanacore N, Di Rosa AE, Morgante L. Levetiracetam in tardive dyskinesia. Clin Neuropharmacol 2006;29(5):265-8.
78. Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Mov Disord 2006;21(11):1998-2001.
79. Zesiewicz TA, Pathak A, Sullivan KL, Shamayev M, Hauser RA. Treatment of chorea with levetiracetam. Eur J Clin Pharmacol 2006;62(1):87.
80. Krebs M, Leopold K, Richter C, Kienast T, Hinzpeter A, Heinz A, Schaefer M. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol 2006;26(3): 347-9.
81. Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neurophar macol 2006;29(6):338-42.
82. Mula M, Sander JWS, Trimble MR. The role of hippocampus sclerosis in antiepileptic drug-related depression in patients with epilepsy. A study on levetiracetam. Seizure 2006;15:405-8.
83. Bilo L, Meo R, Fulvia de Leva M. Levetiracetam in idiopathic generalised epilepsy and porphyria cutanea tarda. Clin Drug Investig 2006;26(6):357-9.
84. Hunt S, Craig J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, Morrison PJ, Morrow J. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy Pregnancy Register. Neurology 2006;67(10):1876-9.
85. Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006;67(12):2253-5.
86. Franzoni E, Garone C, Sarajlija J, Gualandi S, Malaspina E, Cecconi I, Moscano FC, Marchiani V. Open prospective study on oxcarbazepine in epilepsy in children: a preliminary report. Seizure 2006;15(5): 292-8.
87. Pauletto G, Bergonzi P. Triveneto Epilepsy Study Group. Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice. Seizure 2006;15(3):150-5.
88. Kothare SV, Mostofi N, Khurana DS, Mohsem B, Melvin JJ, Hardison HH, Valencia I, Legido A. Oxcarbazepine therapy in very young children: a single-center clinical experience. Pediatr Neurol 2006; 35(3):173-6.
89. Kothare SV, Khurana DS, Mostofi N, Melvin JJ, Marks HG, Valencia I, Legido A. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience. Pediatr Neurol 2006;35(4): 235-9.
90. Kothare SV, Khurana DS, Mostofi N, Melvin JJ, Marks HG, Valencia I, Legido A, Conway CR, Chibnall JT, Nelson LA, McGuire JM, Abraham PF, Baram VY, Grossberg GT, Carroll BJ. An open-label trial of adjunctive oxcarbazepine for bipolar disorder. J Clin Psychopharmacol 2006; 26(1):95-7.
91. Croissant B, Diehl A, Klein O, Zambrano S, Nakovics H, Heinz A, Mann K. A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. Alcohol Clin Exp Res 2006;30(4):630-5.
92. Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, D'Souza J, Wamil A, Lehman RB, Berv D, Linden D. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163(7):1179-86.
93. Donati F, Gobbi G, Campistol J, Rapatz G, Daehler M, Sturm Y, Aldenkamp AP. Oxcarbazepine Cognitive Study Group. Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. Neurology 2006;67(4):679-82.
94. Miller J, Carney P. Central hypothyroidism with oxcarbazepine therapy. Pediatr Neurol 2006;34(3):242-4.
95. Conway CR, Chibnall JT, Nelson LA, McGuire JM, Abraham PF, Baram VY, Grossberg GT, Carroll BJ. An open-label trial of adjunctive oxcarbazepine for bipolar disorder. J Clin Psychopharmacol 2006;26(1):95-7.
96. Striano S, Striano P, Di Nocera P, Italiano D, Fasiello C, Ruosi P, Bilo L, Pisani F. Relationship between serum monohydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy. Epilepsy Res 2006;69(2):170-6.
97. Furlanut M, Franceschi L, Poz D, Silvestri L, Pecorari M. Acute oxcarbazepine, benazepril, and hydrochlorothiazide overdose with alcohol. Ther Drug Monit 2006;28(2):267-8.
98. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006;67:340-2.
99. Rodriguez G, Trent JT, Mirzabeigi M, Zaulyanov L, Bruce J, Vincek V. Toxic epidermal necrolysis in a mother and fetus. J Am Acad Dermatol 2006;55(5 Suppl): S96-8.
100. Mendiratta V, Bhushan P. Phenytoin-induced DRESS with cross-reactivity to carbamazepine in a 10-year-old Indian child. Clin Exp Dermatol 2006;31:720-1.
101. Miller MA, Crystal CS, Patel MM. Hemodialysis and hemoperfusion in a patient with an isolated phenytoin overdose. Am J Emerg Med 2006;24:748-9.
102. LYRICA Study Group. Pregabalin for peripheral neuropathic pain: results of a multicenter, non-comparative, open-label study in Indian patients. Int J Clin Pract 2006;60(9):1060-7.
103. Reuben SS, Buvanendran A, Kroin JS, Raghunathan K. The analgesic efficacy of celecoxib, pregabalin, and their combination for spinal fusion surgery. Anesth Analg 2006;103(5):1271-7.
104. Hamandi K, Sander J W. Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure 2006;15(2):73-8.
105. Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006;16(Suppl 2):S28-33.
106. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006;67(10):1792-1800.
107. Olaizola I, Ellger T, Young P, Bosebeck F, Evers S, Kellinghaus C. Pregabalin-associated acute psychosis and epileptiform EEG-changes. Seizure 2006;15(3):208-10.
108. Malaga I, Sanmarti FX. Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. Epilepsia 2006;47(9):1576-9.
109. Chu ML, Sala DA. The use of tiagabine in pediatric spasticity management. Dev Med Child Neurol 2006;48:456-9.
110. Tombini M, Pacifici L, Passarelli F, Rossini PM. Transient athetosis induced by tiagabine. Epilepsia 2006;47:799-800.
111. Äikiä M, Jutila L, Salmenpera T, Mervaala E, Kälväinan R. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. Epilepsia 2006;47:1121-7.
112. Walsh JK, Zammit G, Schweitzer PK, Ondrasik J, Roth T. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med 2006;7:155-61.
113. Kröll-Seger J, Portilla P, Dulac O, Chiron C. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics 2006;37:325-9.
114. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 2006;46(4):642-8.
115. Zou LP, Ding CH, Fang F, Sin NC, Mix E. Prospective study of first-choice topiramate therapy in newly diagnosed infantile spasms. Clin Neuropharmacol 2006;29: 343-9.
116. Gobbi G, Gaudreau PO, Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psychopharmacol 2006;26:467-73.
117. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF. Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006;66:672-7.
118. Mei D, Ferraro D, Zelano G, Capuano A, Vollono C, Gabriele C, Di Trapani G. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 2006;29:269-75.
119. Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, Fartacek R, Lahmann C, Buschmann W, Tritt K, Bachler E, Mitterlehner F, Pedrosa Gil F, Leiberich P, Rother WK, Egger C. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006;26:61-6.
120. Muehlbacher M, Nickel MK, Kettler C, Tritt K, Lahmann C, Leiberich PK, Nickel C, Krawczyk J, Mitterlehner FO, Rother WK, Loew TH, Kaplan P. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain 2006; 22:526-31.
121. Sofuoglu M, Poling J, Mouratidis M, Kosten T. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2006;184:645-51.
122. Tata AL, Kockler DR. Topiramate for binge-eating disorder associated with obesity. Ann Pharmacother 2006;40:1993-7.
123. Page 2nd RL, Bainbridge JL. Intractable epistaxis associated with topiramate administration. Ann Pharmacother 2006; 40:1462-5.
124. Alonso-Navarro H, Jimenez-Jimenez FJ. Reversible tremor, myoclonus, and fasciculations associated with topiramate use for migraine. Clin Neuropharmacol 2006; 29:157-9.
125. Wheeler SD. Donepezil treatment of topiramate-related cognitive dysfunction. Headache 2006;46:332-5.
126. Zesiewicz TA, Tullidge A, Tidwell J, Sullivan KL, Hauser RA. Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. Clin Neuropharmacol 2006;29:168-9.
127. Sacré A, Jouret F, Manicourt D, Devuyst O. Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase. Nephrol Dial Transplant 2006;21: 2995-6.
128. Winner P, Gendolla A, Stayer C, Wang S, Yuen E, Battisti WP, Nye JS. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache 2006;46:1503-10.
129. Zanotta N, Raggi ME, Radice L, Degrate A, Bresolin N, Zucca C. Clinical experience with topiramate dosing and serum levels in patients with epilepsy. Seizure 2006;15:86-92.
130. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006;5(3):246-56.
131. Zesiewicz TA, Tullidge A, Tidwell J, Sullivan KL, Hauser RA. Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. Clin Neuropharmacol 2006;29:168-9.
132. Lum E, Gorman SK, Slavik RS. Valproic acid management of acute alcohol withdrawal. Ann Pharmacother 2006;40(3): 441-8.
133. Cookson J, Elliott B. The use of anticonvulsants in the aftermath of mania. J Psychopharmacol 2006;20(2 Suppl):23-30.
134. Gerstner T, Woelfing C, Witsch M, Longin E, Bell N, Konig S. Capillary microscopy and hemorheology in children during antiepileptic monotherapy with carbamazepine and valproate. Seizure 2006;15(8):606-9.
135. Galimberti CA, Diegoli M, Sartori I, Uggetti C, Brega A, Tartara A, Arbustini E. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation. Neurology 2006;67(9):1715-7.
136. Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B, Goetze G, Macke A, Lippert G, Klostermann W, Mayer G, Augspach-Hofmann R, Fitzek S, Haensch CA, Reuland M, Koenig SA. Valproic acid induced encephalopathy-19 new cases in Germany from 1994 to 2003-a side effect associated to valproatetherapy not only in young children. Seizure 2006;15(6):443-8.
137. Soares-Fernandes JP, Machado A, Ribeiro M, Ferreira C, Figueiredo J, Rocha JF. Hippocampal involvement in valproate-induced acute hyperammonemic encephalopathy. Arch Neurol 2006;63(8):1202-3.
138. Ristic AJ, Vojvodic N, Jankovic, Sindelic A, Sokic D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 2006;47(12):2183-5.
139. Masmoudi K, Gras-Champel V, Masson H, Andrejak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006;39(1):9-12.
140. Attilakos A, Papakonstantinou E, Schulpis K, Voudris K, Katsarou E, Mastroyianni S, Garoufi A. Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res 2006;71(2-3): 229-32.
141. Morrison PF, Sankar R, Shields WD. Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. Pediatr Neurol 2006;35(5):356-8.
142. Voudris KA, Attilakos A, Katsarou E, Drakatos A, Dimou S, Mastroyianni S, Skardoutsou A, Prassouli A, Garoufi A. Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res 2006;70(2-3):211-7.
143. Sonmez FM, Demir E, Orem A, Yildirmis S, Orhan F, Aslan A, Topbas M. Effect of antiepileptic drugs on plasma lipids, lipo protein (a), and liver enzymes. J Child Neurol 2006;21(1):70-4.
144. Attilakos A, Voudris KA, Garoufi A, Mastroyianni S, Dimou S, Prassouli A, Katsarou E. Effect of sodium valproate monotherapy on serum uric acid concentrations in ambulatory epileptic children: a prospective long-term study. Eur J Paediatr Neurol 2006;10(5-6):237-40.
145. Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, Egberts TC, van den Bemt PM. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006;47(7):1232-6.
146. Keown P, McAllister-Williams H, Young A. A case of pancytopenia. J Psychopharmacol 2006;20(5):690-2.
147. Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, Brand J, Konig S. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 2006;47(7): 1136-43.
148. Stapnes C, Ryningen A, Gjertsen BT, Bruserud ø. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. Acta Oncol 2006;45(3): 346-9.
149. Michoulas A, Tong V, Teng XW, Chang TK, Abbott FS, Farrell K. Oxidative stress in children receiving valproic acid. J Pediatr 2006;149(5):692-6.
150. Voudris K, Attilakos A, Katsarou E, Mastroyianni S, Dimou S, Skardoutsou A, Prassouli A, Garoufi A. Serum total amylase, pancreatic amylase and lipase activities in epileptic children treated with sodium valproate monotherapy. Brain Dev 2006;28(9):572-5.
151. Werlin SL, Fish DL. The spectrum of valproic acid-associated pancreatitis. Pediatrics 2006;118(4):1660-3.
152. Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, Hwang CH, Hall JE, Sachs GS. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006;59(11): 1078-86.
153. Joffe H, Cohen LS, Suppes T, Hwang CH, Molay F, Adams JM, Sachs GS, Hall JE. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 2006;60(12):1378-81.
154. Artama M, Isojärvi JI, Auvinen A. Anti-epileptic drug use and birth rate in patients with epilepsy-a population-based cohort study in Finland. Hum Reprod 2006;21(9): 2290-5.
155. Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf 2006;29(1):1-21.
156. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8.
157. Fattore C, Messina S, Battino D, Croci D, Mamoli D, Perucca E. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steadystate: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res 2006;70(2-3): 153-60.
158. Herranz JL, Arteaga R, AdÃ-n J, Armijo JA. Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics. Eur J Clin Pharmacol 2006; 62(10):805-15.
159. Gerstner T, Bell N, Longin E, Konig SA. Oral rapid loading of valproic acid-an alternative to the usual saturation scheme? Seizure 2006;15(8):630-2.
160. Wilimowska J, Florek E, Piekoszewski W. Disposition of valproic acid in self-poisoned adults. Basic Clin Pharmacol Toxicol 2006;99(1):22-6.
161. Bergemann N, Kress KR, Abu-Tair F, Frick A, Kopitz J. Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol 2006;26(4):432-4.
162. Galimberti CA, Mazzucchelli I, Arbasino C, Canevini MP, Fattore C, Perucca E. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. Epilepsia 2006;47(9):1569-72.
163. Sandson NB, Marcucci C, Bourke DL, Smith-Lamacchia R. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry 2006;163(11):1891-6.
164. Tomson T, Luef G, Sabers A, Pittschieler S, Ohman I. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006;67(7):1297-9.
165. Sheehan NL, Brouillette MJ, Delisle MS, Allan J. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother 2006;40(1):147-50.
166. Allen MH, Hirschfeld RM, Wozniak PJ, Baker JD, Bowden CL. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006;163(2): 272-5.
167. Valente KD, Koiffmann CP, Fridman C, Varella M, Kok F, Andrade JQ, Grossmann RM, Marques-Dias MJ. Epilepsy in patients with Angelman syndrome caused by deletion of the chromosome 15q11-13. Arch Neurol 2006;63(1):122-8.
168. Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006;129(Pt 5): 1281-92.
169. Kinirons P, Cavalleri GL, O'Rourke D, Doherty CP, Reid I, Logan P, Liggan B, Delanty N. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 2006;47(2):311-7.
170. Kinirons P, Cavalleri GL, Singh R, Shahwan A, Acheson JF, Wood NW, Goldstein DB, Sisodiya SM, Doherty CP, Delanty N. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res 2006;70(2-3): 144-52.
171. Fechtner RD, Khouri AS, Figueroa E, Ramirez M, Federico M, Dewey SL, Brodie JD. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. Arch Ophthalmol 2006;124(9): 1257-62.
172. Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68(Suppl 2):S3-9.
173. Leppik IE. Practical prescribing and long-term efficacy and safety of zonisamide. Epilepsy Res 2006;68S:S17-24.
174. Ghaemi SN, Zablotsky B, Filkowski MM, Dunn RT, Pardo TB, Isenstein E, Baldassano CF. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol 2006; 26(4):385-8.
175. Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache 2006;46(5):804-7.
176. Fukushima K, Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia 2006;47(11):1860-4.
177. Kothare SV, Kaleyias J, Mostofi N, Valencia I, Melvin JJ, Hobdell E, Khurana DS, Legido A. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 2006;34(5):351-4.
178. Brodie MJ. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res 2006;68S:S11-6.
179. Sullivan KL, Ward CL, Zesiewicz TA. Zonisamide-induced mania in an essential tremor patient. J Clin Psychopharmacol 2006;26(4):439-40.